Influence of short-term dexamethasone on the efficacy of 177 Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Thorsten DerlinJan M Sommerlath SohnsSebastian SchmuckChristoph HenkenberensChristoph A J von KlotTobias L RossFrank M Bengel

Published in: The Prostate (2020)

We observed high response rates to 177 Lu-PSMA-617 RLT in men with mCRPC. The short-term addition of dexamethasone to 177 Lu-PSMA-617 had no striking antitumor effect but might enhance biochemical responses in patients with bone metastases. Future trials are warranted to test this hypothesis in a prospective setting.

Keyphrases

pet ct
pet imaging
high dose
low dose
positron emission tomography
current status
middle aged
computed tomography